Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab alone and with Nivolumab in Advanced Solid Tumors
NCT01968109Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2013
- Primary completion
- May 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 15
01
Overview
A Phase 2 trial of relatlimab in solid tumor, non-small cell lung cancer (NSCLC), gastric cancer (GC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), sponsored by Bristol Myers Squibb. Started Nov 2013; status: completed.
02
Drugs
relatlimab
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)gastric cancer (GC)hepatocellular carcinoma (HCC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01968109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01968109.